BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $168,177,659 | -2.8% | 2,470,651 | +16.5% | 0.21% | +6.6% |
| Q2 2023 | $173,084,785 | +19.3% | 2,120,352 | +8.4% | 0.20% | +15.1% |
| Q1 2023 | $145,109,093 | +7.2% | 1,955,915 | +19.8% | 0.17% | +7.5% |
| Q4 2022 | $135,315,765 | +26.0% | 1,632,669 | +331.9% | 0.16% | +21.2% |
| Q3 2022 | $107,364,000 | -17.6% | 378,044 | +0.6% | 0.13% | -9.6% |
| Q2 2022 | $130,324,000 | -21.9% | 375,964 | -2.5% | 0.15% | +15.0% |
| Q1 2022 | $166,936,000 | -9.9% | 385,497 | +7.6% | 0.13% | -17.5% |
| Q4 2021 | $185,314,000 | +7.5% | 358,206 | +0.7% | 0.15% | +4.8% |
| Q3 2021 | $172,314,000 | +5.7% | 355,601 | -1.8% | 0.15% | +9.7% |
| Q2 2021 | $162,979,000 | +873.8% | 361,967 | +726.0% | 0.13% | +458.3% |
| Q1 2021 | $16,737,000 | -52.0% | 43,822 | -60.1% | 0.02% | -52.9% |
| Q4 2020 | $34,885,000 | +25.5% | 109,859 | -2.1% | 0.05% | +8.5% |
| Q3 2020 | $27,789,000 | -12.9% | 112,176 | -7.2% | 0.05% | -14.5% |
| Q2 2020 | $31,909,000 | +38.2% | 120,835 | -0.8% | 0.06% | +17.0% |
| Q1 2020 | $23,091,000 | -17.8% | 121,774 | -4.8% | 0.05% | +17.5% |
| Q4 2019 | $28,086,000 | +17.7% | 127,950 | +5.0% | 0.04% | 0.0% |
| Q3 2019 | $23,853,000 | -70.2% | 121,906 | -68.3% | 0.04% | -13.0% |
| Q2 2019 | $80,112,000 | +146.4% | 384,252 | +134.6% | 0.05% | -16.4% |
| Q1 2019 | $32,516,000 | +27.7% | 163,765 | -6.9% | 0.06% | +12.2% |
| Q4 2018 | $25,454,000 | -30.6% | 175,883 | -2.1% | 0.05% | -18.3% |
| Q3 2018 | $36,673,000 | +41.4% | 179,674 | +2.5% | 0.06% | +33.3% |
| Q2 2018 | $25,932,000 | -12.7% | 175,276 | -10.9% | 0.04% | -16.7% |
| Q1 2018 | $29,709,000 | +19.1% | 196,693 | +2.1% | 0.05% | +22.7% |
| Q4 2017 | $24,954,000 | +3.2% | 192,622 | -3.7% | 0.04% | +2.3% |
| Q3 2017 | $24,185,000 | +6.4% | 200,060 | +3.4% | 0.04% | +2.4% |
| Q2 2017 | $22,736,000 | -47.9% | 193,497 | -54.9% | 0.04% | -46.8% |
| Q1 2017 | $43,636,000 | +2.3% | 429,275 | +3.4% | 0.08% | -3.7% |
| Q4 2016 | $42,673,000 | -6.1% | 414,990 | -0.0% | 0.08% | -5.7% |
| Q3 2016 | $45,462,000 | -82.3% | 415,174 | -81.8% | 0.09% | -65.3% |
| Q2 2016 | $256,652,000 | +126.3% | 2,275,896 | +89.6% | 0.25% | +9.6% |
| Q1 2016 | $113,433,000 | +5.1% | 1,200,099 | +0.0% | 0.23% | +3.2% |
| Q4 2015 | $107,955,000 | +0.0% | 1,199,501 | +2.8% | 0.22% | -3.9% |
| Q3 2015 | $107,920,000 | -6.3% | 1,167,205 | -0.2% | 0.23% | +1.3% |
| Q2 2015 | $115,195,000 | -1.8% | 1,169,847 | +0.0% | 0.23% | -0.9% |
| Q1 2015 | $117,304,000 | +8.5% | 1,169,647 | -0.0% | 0.23% | +3.1% |
| Q4 2014 | $108,104,000 | – | 1,169,962 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |